1. Home
  2. GNPX vs SUGP Comparison

GNPX vs SUGP Comparison

Compare GNPX & SUGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • SUGP
  • Stock Information
  • Founded
  • GNPX 2009
  • SUGP 1998
  • Country
  • GNPX United States
  • SUGP Hong Kong
  • Employees
  • GNPX N/A
  • SUGP N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • SUGP
  • Sector
  • GNPX Health Care
  • SUGP
  • Exchange
  • GNPX Nasdaq
  • SUGP NYSE
  • Market Cap
  • GNPX 7.5M
  • SUGP 8.9M
  • IPO Year
  • GNPX 2018
  • SUGP 2024
  • Fundamental
  • Price
  • GNPX $0.29
  • SUGP $0.80
  • Analyst Decision
  • GNPX
  • SUGP
  • Analyst Count
  • GNPX 0
  • SUGP 0
  • Target Price
  • GNPX N/A
  • SUGP N/A
  • AVG Volume (30 Days)
  • GNPX 1.8M
  • SUGP 30.6K
  • Earning Date
  • GNPX 05-12-2025
  • SUGP 07-21-2025
  • Dividend Yield
  • GNPX N/A
  • SUGP N/A
  • EPS Growth
  • GNPX N/A
  • SUGP 1.19
  • EPS
  • GNPX N/A
  • SUGP 0.11
  • Revenue
  • GNPX N/A
  • SUGP $23,446,259.00
  • Revenue This Year
  • GNPX N/A
  • SUGP N/A
  • Revenue Next Year
  • GNPX N/A
  • SUGP N/A
  • P/E Ratio
  • GNPX N/A
  • SUGP $7.62
  • Revenue Growth
  • GNPX N/A
  • SUGP 11.29
  • 52 Week Low
  • GNPX $0.22
  • SUGP $0.52
  • 52 Week High
  • GNPX $3.97
  • SUGP $3.25
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 50.37
  • SUGP 49.03
  • Support Level
  • GNPX $0.26
  • SUGP $0.76
  • Resistance Level
  • GNPX $0.37
  • SUGP $0.86
  • Average True Range (ATR)
  • GNPX 0.04
  • SUGP 0.08
  • MACD
  • GNPX 0.00
  • SUGP -0.02
  • Stochastic Oscillator
  • GNPX 35.04
  • SUGP 14.71

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About SUGP SU GROUP HLDGS LTD

SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment. Geographically operates in Hong Kong, and Other foreign countries, with maximum revenue from Kong Kong.

Share on Social Networks: